Favorable safety profile seen for relapsed/refractory large B-cell lymphoma patients monitored as outpatients or inpatients. HealthDay News — For patients with relapsed/refractory large B-cell ...

Mantle cell lymphoma is the fourth subtype of non-Hodgkin lymphoma that can be treated with this CAR T-cell therapy. Bristol Myers Squibb today announced 1 that FDA has approved lisocabtagene ...

Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published ...

The lifetime health care and societal costs of liso-cel were below the cost-effectiveness threshold of $100,000 per quality-adjusted life-year. Lisocabtagene maraleucel (liso-cel) is cost-effective as ...

Please provide your email address to receive an email when new articles are posted on . Liso-cel induced an 18% complete response/CRi rate among adults with relapsed or refractory CLL or SLL. Median ...

Please provide your email address to receive an email when new articles are posted on . The agent induced a 97% ORR among patients with relapsed or refractory follicular lymphoma. Researchers observed ...

(WASHINGTON, Dec. 28, 2023) – Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat) diffuse large B-cell ...

Please provide your email address to receive an email when new articles are posted on . Liso-cel’s price increased by more than $35,000 dollars between 2022 and 2023. The CAR T-cell therapy’s ICER ...

Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.

Please provide your email address to receive an email when new articles are posted on . In this video, Michael Choi, MD, discusses updated data on the results of liso-cel chimeric antigen receptor ...

FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory (R/R) follicular lymphoma. The FDA has granted Bristol Myers Squibb’s ...